Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04680052
Title A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

follicular lymphoma

splenic marginal zone lymphoma

nodal marginal zone lymphoma

Therapies

Lenalidomide + Rituximab

Lenalidomide + Rituximab + Tafasitamab-cxix

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.